ReviewMedecine et maladies infectieuses2020
Focus on Middle East respiratory syndrome coronavirus (MERS-CoV).
Review in Medecine et maladies infectieuses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 pandemic-related mortality, infection, symptoms, complications, comorbidities, and other aspects of physical health among healthcare workers globally: An umbrella review.International journal of nursing studies · 2022Pooled it
- MERS-Mpro Predictor: A Machine Learning-Based Tool for Rapid Screening of Potential MERS-CoV Main Protease Inhibitors.International journal of molecular sciences · 2026Article
- Review
- Middle East Respiratory Syndrome Coronavirus Could be a Priority Pathogen to Cause Public Health Emergency: Noticeable Features and Counteractive Measures.Environmental health insights · 2024Article
- Article
- The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern.Advances in experimental medicine and biology · 2023Review
- Anti-Infective Secondary Metabolites of the Marine CyanobacteriumMarine drugs · 2022Review
- An overview of literature on COVID-19, MERS and SARS: Using text mining and latent Dirichlet allocation.Journal of information science · 2022Article
- COVID-19 Pathogenesis and Clinical Manifestations.Infectious disease clinics of North America · 2022Review
- Green aspects of photocatalysts during corona pandemic: a promising role for the deactivation of COVID-19 virus.RSC advances · 2022Review
- Novel Coronavirus (SARS-CoV-2) in Water and Environment-A Scoping Review.Life (Basel, Switzerland) · 2022Article
- Non-COVID-19 respiratory viral infection.Breathe (Sheffield, England) · 2022Review
- The direct and indirect effects of bioactive compounds against coronavirus.Food frontiers · 2022Review
- Polymeric Materials as Potential Inhibitors Against SARS-CoV-2.Journal of polymers and the environment · 2022Review
- Persistence of IgG COVID-19 antibodies: A longitudinal analysis.Frontiers in public health · 2022Article
- Review
- The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic.Biomedicines · 2021Review
- The Potential of Lung Epithelium Specific Proteins as Biomarkers for COVID-19-Associated Lung Injury.Diagnostics (Basel, Switzerland) · 2021Review
- The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.IUBMB life · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the first case of human infection by the Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia in June 2012, more than 2260 cases of confirmed MERS-CoV infection and 803 related deaths have been reported since the 16th of October 2018. The vast majority of these cases (71%) were reported in Saudi Arabia but the epidemic has now spread to 27 countries and has not ceased 6 years later, unlike SARS-CoV that disappeared a little less than 2 years after emerging. Due to the high fatality rate observed in MERS-CoV infected patients (36%), much effort has been put into understanding the origin and pathophysiology of this novel coronavirus to prevent it from becoming endemic in humans. This review focuses in particular on the origin, epidemiology and clinical manifestations of MERS-CoV, as well as the diagnosis and treatment of infected patients. The experience gained over recent years on how to manage the different risks related to this kind of epidemic will be key to being prepared for future outbreaks of communicable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.